December 13, 2018 Cell Analysis Tools Clinical Research/Diagn. Life Science Tools

Crown Bioscience Creates Center of Excellence for Bioinformatics, Big Data, and Biomarker Discovery Services

December 18, 2018 ~ Services and Capacity Increase with New Site Opening ~ (San Diego, Calif., December 13, 2018) — Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has recently announced the expansion of its existing translational oncology research capacity by opening... Read more

December 11, 2018 Clinical Research/Diagn.

BD Announces Completion Of Enterprise Level Cybersecurity Assessment From UL

BD FACSLyric™ Flow Cytometer is First BD Product to Earn UL Cybersecurity Assurance Program Certification FRANKLIN LAKES, N.J., Dec. 11, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of an enterprise level cybersecurity assessment from UL. This independent assessment evaluates corporate cybersecurity programs and policies to... Read more

December 10, 2018 Clinical Research/Diagn. Lab Top-10 Product Launch

Thermo Fisher Scientific Launches Complementary Diagnostic Immunoassay Measuring Plazomicin Concentrations

Thermo Fisher Scientific Launches Complementary Diagnostic Immunoassay Measuring Plazomicin Concentrations FREMONT, Calif., Dec. 10, 2018 /PRNewswire/ — Thermo Fisher Scientific has received FDA clearance for its de novo submission of the Thermo Scientific QMS Plazomicin Immunoassay, the first of its kind for complementary diagnostic immunoassays. This quantitative immunoassay measures the concentration of a novel therapeutic... Read more

December 6, 2018 Clinical Research/Diagn. M&A, Partnerships

QIAGEN (Suzhou) and Abcam sign strategic MoU collaboration agreement to co-develop companion diagnostic (CDx) and in vitro diagnostic (IVD) reagents and kits for the Chinese market

Suzhou, China and Cambridge, UK, December 6: Abcam plc, a global innovator in life science reagents and tools, and QIAGEN (Suzhou) Translational Medicine Co., Ltd. (QIAGEN (Suzhou)) have signed a Memorandum of Understanding (MoU) agreement to jointly develop a pipeline of Companion Diagnostic (CDx) and In Vitro Diagnostic reagents and kits, to meet the specific needs... Read more

December 6, 2018 Cell Analysis Tools Clinical Research/Diagn. Product Launch

The Native Antigen Company launches new Zika immunoassays with unprecedented specificity and sensitivity

29 November 2018, Oxford, UK – The Native Antigen Company has launched a series of ground-breaking immunoassays for Zika virus, offering researchers in academia, public health and drug discovery the capability to work with unprecedented levels of specificity and sensitivity. Unlike previous methods, the new assays have little or no cross-reactivity with other flaviviruses, including... Read more

December 6, 2018 Clinical Research/Diagn. M&A, Partnerships Product Launch

QIAGEN announces new collaboration to develop companion diagnostic to guide treatment for patients with PIK3CA-mutated advanced breast cancer

Germantown, Maryland, and Hilden, Germany, December 6, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that a clinical development program is underway with Novartis to bring to market a molecular test as a companion diagnostic to guide the use of the investigational compound BYL719 (alpelisib) in combination with fulvestrant for men... Read more

December 4, 2018 Clinical Research/Diagn. Product Launch

Bio-Techne Releases GMP Rock Inhibitor and CHIR 99021 for Stem Cell Therapy

MINNEAPOLIS, Dec. 4, 2018 /PRNewswire/ — Bio-Techne has further added to its cell therapy portfolio by expanding the range of Tocris Bioscience-branded cGMP small molecules to include the commonly used stem cell compounds, Y-27632 (ROCK inhibitor) and CHIR 99021. Y-27632 is a ROCK inhibitor used in stem cell cryopreservation, expansion and differentiation protocols to enhance stem cell survival... Read more

December 4, 2018 Clinical Research/Diagn. M&A, Partnerships

The EORTC Brain Tumor Group and Protagen AG announce their collaboration to investigate the immuno-competence of long-term Glioblastoma survivors

Zurich, Switzerland and Dortmund, Germany – 4 December 2018 – The European Organization for Research and Treatment of Cancer (EORTC) Brain Tumor Group and Protagen AG today announced a collaboration to utilize Protagen’s Cancer Immunotherapy Array to identify autoantibody biomarkers that investigate the immunological profile and immuno-competence of long-term Glioblastoma survivors. Glioblastoma is the most... Read more

December 4, 2018 Clinical Research/Diagn. M&A, Partnerships

Cofactor Genomics to Provide Solid Tumor Immune Profiling for Genocea Biosciences

— Pilot study to evaluate use of Cofactor assay in Genocea’s neoantigen vaccine clinical trial —December 04, 2018 09:00 AM Eastern Standard Time SAN FRANCISCO–(BUSINESS WIRE)–Cofactor Genomics, a clinical RNA sequencing and translational assay developer, today announced a pilot study to evaluate use of Cofactor’s ImmunoPrismTM assay in Genocea Biosciences’ Phase 1/2a clinical trial testing the... Read more

December 3, 2018 Clinical Research/Diagn.

Sartorius and Immunochina Partner to Advance Immunotherapy Development

December 03, 2018 02:00 AM Pacific Standard Time BEIJING–(BUSINESS WIRE)–Sartorius Stedim Biotech (SSB), a leading international supplier of the biopharmaceutical industry, through its China affiliate, and Beijing-based Immunochina Pharmaceuticals, announced today that both parties have entered into a collaboration. Under the terms of the relationship, Immunochina will gain preferred access to SSB’s bioprocess technology platform... Read more